SCHEMBL2659903

SCHEMBL2659903

COc1ccc(-c2cccc3c(N)c4c(nc23)CN(C2CCCC2)C4=O)c(OC)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 1/20 0.40
▸ BRD7 Q9NPI1 1/20 0.40
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA2 P47869 1/20 0.38
▸ PIK3CA P42336 3/20 0.35
▸ NPY1R P25929 1/20 0.34
▸ NPY5R Q15761 1/20 0.34
▸ GRM5 P41594 2/20 0.34
▸ POLB P06746 3/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ MAOA P21397 2/20 0.33
▸ PLAU P00749 1/20 0.33
▸ MTOR P42345 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ BMPR1A P36894 1/20 0.32
▸ ACVRL1 P37023 1/20 0.32
▸ ACVR1 Q04771 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911805 0.98 BRD9 (0.40) BRD9BRD7GABRG2GABRB3GABRA2
SCHEMBL2669400 0.89 PIK3CA (0.35) BRD9BRD7PIK3CANPY1RNPY5R
SCHEMBL2660827 0.88 PIK3CA (0.47) GABRG2GABRB3GABRA2PIK3CANPY1R
SCHEMBL2658060 0.86 PIK3CA (0.45) GABRG2GABRB3GABRA2PIK3CANPY1R
SCHEMBL2669397 0.86 GABRG2 (0.38) GABRG2GABRB3GABRA2PIK3CANPY1R
SCHEMBL2659508 0.86 GABRG2 (0.44) GABRG2GABRB3GABRA2PIK3CANPY1R
SCHEMBL2657795 0.85 HSP90AA1 (0.39) NPY1RNPY5RGRM5POLBPARP1
SCHEMBL2657187 0.85 BRD9 (0.47) BRD9BRD7GABRG2GABRB3GABRA2
SCHEMBL2662086 0.85 PIK3CA (0.46) PIK3CAMTORBMPR1AACVRL1ACVR1
SCHEMBL2659060 0.85 PIK3CA (0.35) GABRG2GABRB3GABRA2PIK3CANPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF BRD9 3751/4885BRD7 2250/4885GABRG2 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback